You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信立泰(002294.SZ):阿利沙坦酯吲達帕胺緩釋片(復立安)獲得藥品註冊證書

格隆匯6月4日丨信立泰(002294.SZ)公佈,近日,深圳信立泰藥業股份有限公司收到國家藥品監督管理局覈準簽發的阿利沙坦酯吲達帕胺緩釋片(復立安®)藥品註冊證書。

阿利沙坦酯吲達帕胺緩釋片(復立安®)用於治療原發性高血壓。復立安®爲國產原研ARB/利尿劑類複方緩釋製劑(項目代碼:SAL0108),阿利沙坦酯和吲達帕胺兩藥聯用,可以降低利尿劑的低血鉀和尿酸增加等不良反應,起到增效減毒的作用,適用於鹽敏感性高血壓,老年和高齡老年高血壓,單純收縮期高血壓,高血壓合併糖尿病、肥胖或代謝綜合徵,慢性心力衰竭等患者。

阿利沙坦酯吲達帕胺緩釋片(復立安®)上市後,將有針對性地覆蓋不同細分領域的高血壓患者,與信立坦(阿利沙坦酯片)、信超妥(沙庫巴曲阿利沙坦鈣片)、復立坦®(阿利沙坦酯氨氯地平片)在適用人羣和相關疾病領域形成戰略互補,滿足更多臨牀需求,造福廣大的患者人羣,並進一步提升公司在心血管慢病治療領域的綜合競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account